恩替卡韦治疗HBeAg阳性慢性活动性乙型肝炎的疗效及安全性

Efficacy and safety of entecavir on HBeAg positive chronic active hepatitis B

目的探讨恩替卡韦治疗乙型肝炎e抗原（HBeAg）阳性慢性活动性乙型肝炎的疗效及安全性。方法选取HBeAg阳性慢性活动性乙型肝炎患者120例为研究对象，并随机分为研究组和对照组，研究组使用恩替卡韦进行治疗，对照组使用阿德福韦酯进行治疗。结果研究组在治疗的各时期HBV—DNA阴转率均高于对照组（P均〈0．05）；研究组治疗后第12、24、48周，HBeAg转换率均高于对照组（P均〈0．05）；研究组治疗各阶段的肝功能改善情况优于对照组（P〈0．05），不良反应发生率低于对照组（P〈0．05）。结论应用恩替卡韦抗病毒治疗HBeAg阳性慢性活动性乙型肝炎，疗效优于阿德福韦酯，可有效提高治疗效果，值得临床推广应用。

Objective To study the effect and safety of entecavir on HBeAg positive hepatitis B virus （HBV） infection. Methods A total of 120 patients with HBeAg positive HBV were selected as re- search objects, and were randomly divided into study group and control group. Patients in study group were treated with entecavir, patients in control group were treated with adefovir dipivoxil. Results The negative conversion rate of HBV-DNA in study group was significantly higher than that in control group at every stage of treatment （P 〈 0. 05 ）. After 12, 24 and 48 weeks of treatment, the HBeAg conversion rate in study group was significantly higher than that in control group （ all P 〈 0. 05 ）. The liver improvement of the patients in study group were significantly superior to those in control group at ever stage of treatment （ P 〈 0. 05 ）. The incidence of adverse reactions of study group was significantly lower than that of control group （P 〈 0. 05 ）. Conclusions Entecavir antiviral therapy for HBeAg positive chronic active HBV can effectively improve the therapeutic effect, which is superior to adefovir dipivoxil. It is worthy of promotion and application clinically.